Trilogy Capital Inc. Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Trilogy Capital Inc. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 91.5% in the 1st quarter, Holdings Channel reports. The firm owned 4,392 shares of the company’s stock after purchasing an additional 2,099 shares during the period. Trilogy Capital Inc.’s holdings in Johnson & Johnson were worth $695,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Alerus Financial NA lifted its stake in shares of Johnson & Johnson by 1.7% in the 3rd quarter. Alerus Financial NA now owns 4,299 shares of the company’s stock valued at $670,000 after purchasing an additional 71 shares during the last quarter. Elevatus Welath Management lifted its stake in shares of Johnson & Johnson by 29.1% in the 3rd quarter. Elevatus Welath Management now owns 1,802 shares of the company’s stock valued at $281,000 after purchasing an additional 406 shares during the last quarter. Legacy Advisors LLC lifted its stake in shares of Johnson & Johnson by 6.3% in the 3rd quarter. Legacy Advisors LLC now owns 72,571 shares of the company’s stock valued at $11,303,000 after purchasing an additional 4,279 shares during the last quarter. Lakeshore Financial Planning Inc. acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at $460,000. Finally, KPP Advisory Services LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at $1,828,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on JNJ. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research note on Monday, June 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday. Finally, The Goldman Sachs Group began coverage on Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target on the stock. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $174.07.

Johnson & Johnson Trading Up 0.2 %

JNJ opened at $146.42 on Tuesday. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The company has a market cap of $352.39 billion, a P/E ratio of 9.13, a PEG ratio of 2.43 and a beta of 0.52. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The business’s 50-day simple moving average is $148.14 and its 200-day simple moving average is $154.05.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.68 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date of this dividend was Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.